Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

CYTH

Cyclo Therapeutics (CYTH)

Cyclo Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CYTH
DateTimeSourceHeadlineSymbolCompany
08/02/202500:05Business WireCyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)NASDAQ:CYTHCyclo Therapeutics Inc
15/01/202500:05Business WireCyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025NASDAQ:CYTHCyclo Therapeutics Inc
11/12/202423:00GlobeNewswire Inc.Rafael Holdings Reports First Quarter Fiscal 2025 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
15/11/202400:05Business WireCyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
07/11/202411:14GlobeNewswire Inc.Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
21/10/202423:00GlobeNewswire Inc.Pacira BioSciences Appoints Shawn Cross as Chief Financial OfficerNASDAQ:CYTHCyclo Therapeutics Inc
05/09/202423:05Business WireCyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)NASDAQ:CYTHCyclo Therapeutics Inc
26/08/202423:37PR Newswire (US)Kuehn Law Encourages CYTH, ARCH, CEIX, and VGR Investors to Contact Law FirmNASDAQ:CYTHCyclo Therapeutics Inc
22/08/202423:37Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:CYTHCyclo Therapeutics Inc
22/08/202423:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTHCyclo Therapeutics Inc
22/08/202420:50GlobeNewswire Inc.Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger AgreementNASDAQ:CYTHCyclo Therapeutics Inc
22/08/202420:50Business WireRafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger AgreementNASDAQ:CYTHCyclo Therapeutics Inc
21/08/202403:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTHCyclo Therapeutics Inc
21/08/202403:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTHCyclo Therapeutics Inc
21/08/202403:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTHCyclo Therapeutics Inc
21/08/202403:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTHCyclo Therapeutics Inc
21/08/202403:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTHCyclo Therapeutics Inc
21/08/202403:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTHCyclo Therapeutics Inc
21/08/202403:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTHCyclo Therapeutics Inc
15/08/202423:00Business WireCyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
15/08/202407:28Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYTHCyclo Therapeutics Inc
29/07/202423:05Business WireCyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent OfficeNASDAQ:CYTHCyclo Therapeutics Inc
18/07/202404:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTHCyclo Therapeutics Inc
25/06/202423:25Business WireCyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024NASDAQ:CYTHCyclo Therapeutics Inc
15/06/202406:01GlobeNewswire Inc.Rafael Holdings Reports Third Quarter Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
30/05/202423:00Business WireCyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1NASDAQ:CYTHCyclo Therapeutics Inc
16/05/202422:05Business WireCyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
19/03/202400:05Business WireCyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
15/03/202400:34Business WireCyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s DiseaseNASDAQ:CYTHCyclo Therapeutics Inc
14/03/202408:04GlobeNewswire Inc.Rafael Holdings Reports Second Quarter Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CYTH